|
|
|
| Risk factors of Endometrial Cancer in Patients Receiving Endocrine Therapy after Breast Cancer Surgery |
| HAN Wen-he, WANG Xiao-tong, CHEN Yan-li |
| Shandong Provincial Third Hospital,Jinan Shandong,250031,China |
|
|
|
|
Abstract 【Objective】To analyze the risk factors of endometrial cancer in patients undergoing endocrine therapy after breast cancer surgery. 【Methods】The clinical data of 288 patients with endometrial lesions after endocrine therapy in our hospital from January 2015 to March 2020 were retrospectively analyzed. According to different types of lesions, they were divided into endometrial polyps group ( n =209), endometrial hyperplasia group ( n =47) and endometrial carcinoma group ( n =32). The risk factors of endometrial cancer were analyzed retrospectively. 【Results】There were significant differences in age, endometrial thickness, menopause and abnormal uterine bleeding among the three groups ( P <0.05); endometrial thickness, menopause and abnormal uterine bleeding were independent risk factors for endometrial cancer in patients receiving endocrine therapy after breast cancer surgery ( P <0.05); when endometrial thickness ≥ 7.760 mm, the sensitivity of predicting endometrial cancer was 59.4%,the specificity was 73.9%, the sensitivity of menopause and abnormal uterine bleeding in predicting endometrial cancer was 75.0% and 71.9% respectively.The specificity was 39.1% and 24.5% respectively.【Conclusion】Menopause, abnormal uterine bleeding and endometrial thickness ≥ 7.760 mm were independent risk factors for endometrial cancer in patients receiving endocrine therapy after breast cancer surgery.
|
|
Received: 26 October 2020
|
|
|
|
|
|
[1] 李贺,郑荣寿,张思维,等. 2014年中国女性乳腺癌发病与死亡分析[J].中华肿瘤杂志, 2018, 40(3): 166-171.
[2] Burstein HJ, Lacchetti C, Anderson H, et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update[J]. J Clin Oncol, 2019,37(5):423-438.
[3] Burstein HJ.Adjuvant endocrine therapy for women with hormone receptorpositive breast cancer: american society of clinical oncology clinical practice guideline focused update[J]. J Clin Oncol, 2014,32:2255-2269.
[4] Davies C.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013,381(9869):805-816.
[5] Kyvernitakis I, Kostev K, Hadji P.The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre-and postmenopausal women with breast cancer[J]. Osteoporos Int, 2018,29(11):2557-2564.
[6] Chen JY.Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study[J]. J Cancer, 2014, 5(2):151-155.
[7] Ng HS, Koczwara B, Roder D, Niyonsenga T, et al . Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study[J]. J Comorb, 2018,8(1):16-24.
[8] Hernandez Ramon EE, Sandoval NA, John K, et al .Tamoxifen DNA adduct formation in monkey and human Tamoxifen DNA adduct formation in monkey and human reproductive organs[J]. Carcinogenesis, 2014, 35(5):1172-1176.
[9] Fleming CA, Heneghan HM, O'Brien D, et al . Meta analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy[J]. Br J Surg, 2018,105(9):1098-1106.
[10] Saccardi C, Gizzo S, Patrelli TS, et al . Endometrial surveillance in tamoxifen users: role, timing and accuracy of hysteroscopic investigation: observational longitudinal cohort study[J]. Endocr Relat Cancer, 2013, 20(4): 455-462. |
|
|
|
2021, Vol. 38 
